Taken together, these studiespoint to possible direct effects of PPAR agonists on the vasculature thatimpedes pathogenic pathways implicated in the development of atherosclerosis,including inflammation, oxidative stress, metalloprotease activity, AGEaccumulation, and activation of the RAS. The gene discussed is PPARA; the disease is atherosclerosis.